|
|
|
| Investigation on the medication compliance of patients with chronic hepatitis B receiving free Entecavir |
| TAO Junxiu1,2 LI Xiaodong1,2 WAN Changxiu1,2 WANG Hui1,2 WU Huikun1,2 ZHOU Qiong1,2 LIANG Haili1,2 WANG Ting1,2 |
1.Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Hubei Province Academy of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China |
|
|
|
|
Abstract Objective To investigate status of the medication compliance of patients with chronic hepatitis B receiving free Entecavir. Methods A total of 401 patients with chronic hepatitis B receiving free Entecavir and participated in the clinical study of Hubei Provincial Hospital of Traditional Chinese Medicine from June 2012 to April 2016 were taken as objects, followed-up for 48 weeks, the investigation and quality control was conducted according to the dose of drug use and the amount of drug recovery from the patients' medication log card, so as to evaluate the medication compliance of patients. Results The medication compliance of 24, 36 weeks in patients with chronic hepatitis B was better than those of 12, 48 weeks (P ＜ 0.01). The compliance rate of one year was 98.4%, full compliance was accounted for 32.0%, and the percentage of compliance ＞95% d was 92.4%. The medication compliance of patients with hepatitis B cirrhosis was better than that of mild to moderate chronic hepatitis B (P ＜ 0.01). The main reason of missing drugs was forgotten. Conclusion Although the medication compliance of patients with chronic hepatitis B receiving free Entecavir is high, but the patients still lack the knowledge about the disease. It is necessary to strengthen the patients' cognitive education of the disease and improve the compliance.
|
|
|
|
|
|
[1] 参加慢性乙型肝炎长期治疗讨论会专家组.核苷（酸）类药物治疗慢性乙型肝炎的长期性[J/CD].中华实验和临床感染病杂志：电子版，2015，9（2）：1-6.
[2] Marcellin P，Asselah T. Long-term therapy for chronic hepatitis B：hepatitis B virus DNA suppression leading to cirrhosis reversal [J]. J Gastroenterol Hepatol，2013，28（6）：912-923.
[3] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015更新版）[J].中华肝脏病杂志，2015，23（12）：888-905.
[4] Osterberg L，Blaschke T. Adherence to medication [J]. N Engl J Med，2005，353（5）：487-497.
[5] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].中华肝脏病杂志，2011， 19（1）：13-24.
[6] 王晓霞，李育民，高瑾，等.药物临床试验中受试者的依从性问题研究[J].中国药物与临床，2009，9（6）：507-508.
[7] 董南，何波，庄辉.慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查[J].肝脏，2009，14（1）：8-10.
[8] 李洪杰，范小玲，李蕴茹，等.慢性乙型肝炎患者疾病相关认知度及抗病毒治疗现状调查分析[J].中国肝脏病杂志：电子版，2014，6（4）：1-3.
[9] 参加乙型肝炎病毒耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中华肝脏病杂志，2013，21（1）：15-22.
[10] 刘红丽，余维，罗叶昕.延续护理对癌痛患者居家自我管理的效果观察[J].护理学报，2017，24（6）：64-66.
[11] 任玉莲，张志敏.护理干预对慢性乙型肝炎患者抗病毒治疗依从性的影响探讨[J].现代中西医结合杂志，2014， 23（15）：1693-1695.
[12] 刘晶，孙玲，勇伟娜.乙肝肝硬化合并肝性脑病患者延续护理[J].护理学报，2017，24（2）：49-50.
[13] 叶丽华，胡兆琴，李正莲.慢性乙型肝炎患者诊断治疗依从性行为调查[J].实用肝脏病杂志，2013，16（2）：155-156.
[14] Han SH，Jing W，Mena E，et al. Adherence，persistence，healthcare utilization，and cost benefits of guideline-recommended hepatitis B pharmacotherapy [J]. J Med Econ，2012，15（6）：1159-1166.
[15] Chotiyaputta W，Hongthanakorn C，Oberhelman K，et al. Adherence to nucleos（t）ideanalogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs [J]. J Viral Hepat，2012，19（3）：205-212.
[16] 张栩，汪维娜.慢性乙型肝炎患者抗病毒治疗的依从性分析[J].中国现代医生，2016，54（10）：92-95.
[17] 安雪梅，杨再国.“知信行理论”对高血压患者自我效能及其服药依从性的影响[J].成都医学院学报，2015，10（4）：464-466.
[18] 车源霞.我院门诊老年糖尿病患者用药依从性差相关因素的调查分析[J].中国药房，2017，28（6）：729-732.
[19] 章晓云，彭丽娟.利用手机闹铃提高慢性乙型肝炎患者服药依从性的效果观察[J].护理学报，2011，18（2A）：54-56.
[20] Peng J，Yin J，Cai S，et al. Factors associated with adherence to nucleos（t）ide analogs in chronic hepatitis B patients：results from a 1-year follow-up study [J]. Patient Prefer Adherence，2015，9：41-45.
[21] 周树军，王云梅，王振娟，等.出院后药学干预对基层医院PCI术后冠心病患者用药依从性及其预后的影响[J].中国药房，2017，28（8）：1126-1129. |
|
|
|
